Den Europæiske Union - dansk - EMA (European Medicines Agency)

recordati rare diseases - mercaptaminbitartrat - cystinosis - andre alimentary tract and metabolism produkter, - cystagon er indiceret til behandling af bevist nefropatisk cystinose. cysteamin reducerer cystinakkumulering i nogle celler (f.eks. leukocytter, muskel- og leverceller) hos nephropatiske cystinose patienter, og når behandlingen påbegyndes tidligt forsinker det udviklingen af ​​nyresvigt.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - topiramat - filmovertrukne tabletter - 100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - topiramat - filmovertrukne tabletter - 200 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, squamous cell - antineoplastiske midler - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - itraconazol - kapsler, hårde - 100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - topiramat - filmovertrukne tabletter - 100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - topiramat - filmovertrukne tabletter - 200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

janssen-cilag a/s - topiramat - filmovertrukne tabletter - 50 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astellas pharma europe b.v. - gilteritinib fumarate - leukæmi, myeloid, akut - antineoplastiske midler - xospata er angivet som monoterapi til behandling af voksne patienter med recidiverende eller refraktær akut myeloid leukæmi (aml) med en mutation flt3.